Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

The International Monetary Fund (IMF) is projecting the global economic growth at 3.3 percent in both 2025 and 2026, below ...

The Dutch economy is projected to grow by a modest 1.3% in 2025, primarily fuelled by consumption. Weak external demand is ...

More than 50,000 people were under evacuation orders or warnings Wednesday as a huge and fast-moving wildfire swept through rugged mountains north of Los Angeles, as parched Southern California ...

A "major" new report is offering the most robust insights yet on the growing problems of cost and accessibility for homeowner ...

One reason is the fact that much research related to ovarian cancer has focused on strategies combining chemotherapy with ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

In an era where maintaining optimal health has become a priority for many, the search for practical solutions to manage blood ...

Are you battling hypertension? If you are, you are not alone. According to WHO, over the last 30 years, the number of people aged 30-79 with hypertension has increased from 650 million to a worrisome ...

Keep reading to learn more about this tea, including its potential benefits and side effects ... that the combined effects of bergamot could benefit digestion, more robust studies are needed ...